Alembic Change To Netincome from 2010 to 2024

APLLTD Stock   1,093  51.35  4.93%   
Alembic Pharmaceuticals' Change To Netincome is decreasing over the years with stable fluctuation. Overall, Change To Netincome is expected to go to about 300.9 M this year. From 2010 to 2024 Alembic Pharmaceuticals Change To Netincome quarterly data regression line had arithmetic mean of  127,339,600 and r-squared of  0.03. View All Fundamentals
 
Change To Netincome  
First Reported
2010-12-31
Previous Quarter
286.6 M
Current Value
300.9 M
Quarterly Volatility
459 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Alembic Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alembic Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.9 B, Interest Expense of 590 M or Selling And Marketing Expenses of 5.1 B, as well as many indicators such as . Alembic financial statements analysis is a perfect complement when working with Alembic Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Alembic Pharmaceuticals Technical models . Check out the analysis of Alembic Pharmaceuticals Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Alembic Stock

Alembic Pharmaceuticals financial ratios help investors to determine whether Alembic Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alembic with respect to the benefits of owning Alembic Pharmaceuticals security.